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Abstract
Background: De Quervain's tenosynovitis is a stenosing tenosynovitis of the first dorsal compartment of
the wrist and leads to wrist pain and to impaired function of the wrist and hand. It can be treated by
splinting, local corticosteroid injection and operation. In this study effectiveness of local corticosteroid
injections for de Quervain's tenosynovitis provided by general practitioners was assessed.
Methods: Participants with de Quervain's tenosynovitis were recruited by general practitioners. Short-
term outcomes (one week after injections) were assessed in a randomised, placebo-controlled trial. Long-
term effectiveness was evaluated in an open prospective cohort-study of steroid responders during a
follow-up period of 12 months. Participants were randomised to one or two local injections of 1 ml of
triamcinolonacetonide (TCA) or 1 ml of NaCl 0.9% (placebo). Non-responders to NaCl were treated with
additional TCA injections. Main outcomes were immediate treatment response, severity of pain,
improvement as perceived by participant and functional disability using sub items hand and finger function
of the Dutch Arthritis Impact Measurement Scale (Dutch AIMS-2-HFF).
Results: 11 general practitioners included 21 wrists in 21 patients. The TCA-group had better results for
short-term outcomes treatment response (78% vs. 25%; p = 0.015), perceived improvement (78% vs. 33%;
p = 0.047) and severity of pain (4.27 vs. 1.33; p = 0.031) but not for the Dutch-AIMS-HFF (2.71 vs. 1.92;
p = 0.112). Absolute risk reduction for the main outcome short-term treatment response was 0.55 (95%
CI: 0.34, 0.76) with a number needed to treat of 2 (95% CI: 1, 3). In the cohort of steroid responders (n
= 12) the beneficial effects of steroid injections were sustained during the follow-up of 12 months
regarding severity of pain (p = 0.67) and scores of Dutch AIMS-2-HFF (p = 0.36), but not for patient
perceived improvement (p = 0.02). No adverse events were observed during the 12 months of follow-up.
Conclusion: One or two local injections of 1 ml triamcinolonacetonide 10 mg/ml provided by general
practitioners leads to improvement in the short term in participants with de Quervain's tenosynovitis
when compared to placebo. The short-term beneficial effects of steroid injections for symptoms were
maintained during the follow-up after 12 months.
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Background
De Quervain's tenosynovitis is a condition that causes
wrist pain and that can lead to disfunction of the affected
hand. It is caused by impaired gliding of the tendons of
the abductor pollicis longus (APL) and extensor pollicis
brevis (EPB) muscles[1]. This is most probably caused by
thickening of the extensor retinaculum (the thickened
part of the general tendon sheath that holds the tendons
of the extensor muscles in place) of the wrist.
Fritz de Quervain, a Swiss physician, is given credit for first
describing this condition with a report of five cases in
1895 and eight additional cases in 1912[2,3]. Although
the term stenosing tenosynovitis is frequently used,
pathophysiology of de Quervain's disease does not
involve inflammation since on histopathological exami-
nation mainly degenerative changes such as myxoid
degeneration, fibrocartilagenous metaplasia and deposi-
tion of mucopolysaccharide are seen[4].
The diagnosis is made by history and physical examina-
tion. Symptoms consist of pain or tenderness at the radial
styloid sometimes radiating to the thumb, forearm or
shoulder and on physical examination there might be
swelling at the radial styloid with tenderness and crepita-
tions on palpation. Finkelstein's test (deviating the wrist
to the ulnar side, while grasping the thumb, results in
pain) is in typical cases positive. A positive Finkelstein's
test has a between observer repeatability (k) of 0.79[5].
Unfortunately there is no golden diagnostic confirmatory
test for de Quervain's tenosynovitis. In the literature a
variety of terminology (e.g. tendinitis, peritendinitis, ten-
osynovitis, tenovaginitis) and case-definitions are used
for this condition. In 1998 and 2001 efforts have been
made to construct reliable classifications and case-defini-
tions for soft-tissue rheumatic disorders of the upper
limb, including de Quervain's tenosynovitis [5-7].
In a large community based study from the United King-
dom, the prevalence of de Quervain's tenosynovitis was
0,5% for men and 1,3% for women[8]. It was associated
with considerable impact on daily activities and health
seeking behaviour. The prevalence and incidence of
patients with de Quervain's tenosynovitis in primary care
are not known.
De Quervain's tenosynovitis can be treated by operative
and non-operative treatment. Operative therapy (slitting
or removing a strip of the tendon sheet) has been reported
to be effective with a 91% cure rate in non-controlled
studies, but is more invasive and associated with higher
costs and the possibility of surgical complications[9].
The effectiveness of injection therapy is often attributed to
anti-inflammatory effects of corticosteroids but the exact
mechanism of action remains unclear. A recent Cochrane
review found one controlled clinical trial by Avci of 18
participants (all pregnant or lactating women) that com-
pared one steroid injection with methylprednisolone and
bupivacaine to splinting with a thumb spica[10,11]. All
patients in the steroid injection group (9/9) achieved
complete relief of pain whereas none of the patients in the
thumb spica group (0/9) had complete relief of pain, one
to six days after intervention (number needed to treat to
benefit (NNTB) = 1. However, it was also concluded that
the applicability of these findings to daily clinical practice
may be limited, as they were based on only one trial with
a small number of included participants, the methodolog-
ical quality was poor and only pregnant and lactating
women participated in the included study. In another sys-
tematic review of effectiveness of corticosteroid injection
for de Quervain's tenosynovitis that included seven obser-
vational studies (with totally 459 wrists), 83% of the 226
wrists that received injection alone were cured, 61% of the
101 wrists that received injection and splint immobiliza-
tion were cured and only 14% of those who received
splinting alone were cured[12]. A study that compared
effectiveness of one injection of 10 mg triamcinolonaceto-
nide injection to triamcinolonacetonide injections com-
bined with 200 mg oral nimesulide during seven days
found no significant differences between the two groups
and success rate after three weeks was 67% in the
nimesulide + triamcinolone group and 68% in the triam-
cinolone alone group[13].
Other conservative treatment modalities, such as heat,
cold, diathermy, strapping, splints, rest, massage, counter-
irritants and medications were found not to be effec-
tive[1].
The lack of high quality controlled trials and data regard-
ing effectiveness of local corticosteroid injections pro-
vided by general practitioners prompted us to design a
randomised, placebo controlled trial in primary care to
evaluate effectiveness of local steroid injections for de
Quervain's tenosynovitis.
Methods
This trial is part of a larger study called the Groningen
Hand and Wrist Injection Therapy Trial (HAWITT) in
which efficacy, safety and feasibility of corticosteroid
injections for carpal tunnel syndrome, de Quervain's ten-
osynovitis and trigger finger in general practice were
assessed. In this report the results for de Quervain's teno-
synovitis are described.
Approval for the HAWITT-study was given by the medical
ethics committee of the University Medical Center Gron-
ingen (METc 2002/020c).BMC Musculoskeletal Disorders 2009, 10:131 http://www.biomedcentral.com/1471-2474/10/131
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Setting
Patients were recruited from the practices of 11 general
practitioners in the northern part of the Netherlands.
Patient recruitment, in- and exclusion criteria
Patients presenting to the participating general practition-
ers with a clinical diagnosis of de Quervain's tenosynovitis
were recruited in the period of 2003-2005. A clinical diag-
nosis of de Quervain's tenosynovitis was defined as pain
or tenderness at the radial styloid combined with either a
positive Finkelsteins test or crepitations on palpation at
the radial styloid.
Exclusion criteria were being of minor age (< 18), pres-
ence of an absolute contraindication for corticosteroid
injection, prior treatment in the last six months with ster-
oid injection and/or surgery at the same anatomical loca-
tion, possible traumatic or neoplastic origin of symptoms,
inability to fill in follow-up forms or absence of self deter-
mination in the participating patient. After written
informed consent was obtained by the patient's general
practitioner, baseline data were collected and patients
were randomised to either steroid or saline injection.
Intervention and injection technique
Participants received one or two local injections with
either 1 ml triamcinolonacetonide 10 mg/ml (experimen-
tal intervention) or 1 ml NaCl 0.9% (control interven-
tion). One millilitre of the trial medication was deposed
after inserting the needle along the line of the tendon, just
proximal or distal to the styloid, at the site of maximum
tenderness.
All general practitioners involved in the study were
offered a two-hour course on diagnosing de Quervain's
tenosynovitis and the technique of injection therapy,
using an arm phantom for instruction.
Randomisation and allocation concealment
Randomisation was realized using an electronic online
randomisation tool developed by G. Urbaniak (http://
www.randomizer.org, accessed on 22.12.2002). Block
randomisation was performed by creating 5 sets of blocks
of 10 random numbers. Even numbers corresponded with
active trial medication and uneven numbers with placebo
to ensure equal numbers of allocation to active and pla-
cebo treatment. Treatment allocation was written on a
paper and enclosed in an opaque and sealed envelope.
After inclusion of a patient a pharmacy assistant at a
remote location who was not involved in the study drew
an envelope and sent the allocated trial medication to the
injecting general practitioner.
Study design, blinding and bail-out treatment
Every patient with a clinical diagnosis of de Quervain's
tenosynovitis presenting to one of the participating gen-
eral practitioners was asked to participate in the trial. After
applying inclusion and exclusion criteria assessment of
baseline clinical characteristics took place by the patient's
own general practitioner, who also performed the blinded
assessment of the short-term follow-up two weeks after
the intervention. In order to guarantee blinding of short-
term outcome assessment (after randomisation) the trial
medication was injected one week after inclusion by a sec-
ond independent general practitioner. If the result of the
first injection was not satisfactory in the participant's
opinion, the participants were given a second injection by
the other independent general practitioner one week later.
Two weeks after the injections with the trial medication
the participants were instructed to return to their own gen-
eral practitioner for assessment of short-term outcomes.
Because a placebo look-alike of the triamcinolonaceto-
nide injection suspension could not be manufactured,
blinding was realised by applying the injection while the
participant was blindfolded.
Bail-out treatment
If during short term outcome assessment the response to
the blinded injection(s) was insufficient according to
agreement between the patient and general practitioner
blinding was discontinued and the trial centre was asked
whether injected trial medication consisted the active sub-
stance (TCA) or control treatment (NaCl). Participants
who were randomized to TCA with no response to
blinded injections were referred to secondary care for
operative treatment and not included in the long-term
analysis.
In case of insufficient response after injection of NaCl,
one or two additional injections with TCA (bail-out treat-
ment) with weekly intervals were given without blinding.
In case of insufficient response to one or two bailout injec-
tions, participants were referred to secondary care for
operative treatment and not included in the long-term fol-
low-up analysis. Introducing bailout treatment for non-
responders to NaCl was required, as the medical ethics
committee considered it to be unethical to leave patients,
who received placebo treatment with no improvement in
symptoms after intervention, untreated.
Outcomes measurements
During short term assessment primary outcome measure-
ments were recorded. Primary outcomes were:
1. direct treatment response (based on consensus between
physician and participant), one week after injection treat-
ment:
• 0 = no response
￿ 1 = partial response, but not satisfactory, warranting
further treatmentBMC Musculoskeletal Disorders 2009, 10:131 http://www.biomedcentral.com/1471-2474/10/131
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￿ 2 = partial response, satisfactory, not warranting fur-
ther treatment
￿ 3 = complete resolution of symptoms and signs
2. severity of pain at the radial styloid during the week
prior to measurement using a numerical rating scale: 0 =
no pain; 10 = severe pain
3. Functional status was recorded by using the sub items
hand and finger function of the Dutch version of the sec-
ond version of the Arthritis Impact Measurement Scale
(DUTCH AIMS-2-HFF)[14].
4. improvement as perceived by participant, using a 5-
point ordinal scale:
￿ -2 = much worse
￿ -1 = worse
￿ 0 = not better/not worse
￿ +1 = better
￿ +2 = much better
The occurrence of adverse events (quantitative and quali-
tative) at short-term assessment was a secondary outcome.
Follow up measurements were performed by sending
questionnaires to participating patients 1, 3, 6 and 12
months after the last injection and consisted of the same
primary outcome measures as during short term assess-
ment except for direct treatment response.
Sample size and data analysis
Calculations of sample size were based on a two-sided
alpha of 0.05, a statistical power of 0.90. The proportion
of patients treated with steroid injection with satisfactory
response or complete resolution after two injections was
expected to be at least 70%, extrapolated from prior pro-
spective studies. Adequate treatment response to placebo
treatment was expected to be 20%. Based on these calcu-
lations we aimed to recruit 25 patients for each treatment
group. An intention tot treat analysis was used.
Table 1: Baseline characteristics of participants with de Quervain's tenosynovitis
NaCl (n = 12) TCA(n = 9)
mean age (SD) 52.3 (12.6) 51.2 (20.2)
sex (female/male)* 10/12 3/9
median (min, max) duration of symptoms (weeks) 8 (2, 50) 5 (3, 24)
affected side (right/left) 8/3 4/5
dexterity (right/left) 11/0 7/2
Median (min, max) Dutch AIMS-HFF score 2.6 (1.0, 3.6) 2.4 (1.0, 4.5)
Median (min, max) severity of pain 7 (4, 10) 7 (2, 8)
* p value = 0.32 (Fisher's Exact test)
SD = standard deviation
NaCl = NaCl 0.9% (saline)
TCA = triamcinolonacetonide 10 mg/ml
flowchart: flow of participants Figure 1
flowchart: flow of participants. TCA = 1 ml triamci-
nolonacetonide 10 mg/ml NaCl = 1 ml NaCl (0.9%).BMC Musculoskeletal Disorders 2009, 10:131 http://www.biomedcentral.com/1471-2474/10/131
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For continuous data the student T-test was used if the dis-
tribution was normal and Mann-Witney U test if there was
not a normal distribution. For categorical data Fisher's
exact test was used. Friedmann's test was used to compare
observations repeated on the same subjects and to test if
the distributions are the same across repeated measures if
a non-normal distribution of outcome data was sus-
pected. Significance was accepted at a probability value of
< 0.05. To calculate the number to treat the formula NNT
= 1/ARR was used, where ARR (Absolute Risk Reduction)
= CER (Control Group Event Rate) - EER (Experimental
Group Event Rate). Missing values were imputated using
the expectation maximation score. Data were analysed
using the statistical software SPSS version 14 (SPSS Inc
Chicago, Illinois, USA).
Results
Inclusion of participants and baseline characteristics
During the inclusion period of 2 years (January 2003 to
January 2005) 21 participants who fulfilled inclusion cri-
teria were recruited by 11 general practitioners of the
HAWITT-trial. At baseline assessment the two interven-
tion-groups were found to be comparable regarding
potentially prognostic indicators and differed only in
male to female ratio (table 1). After randomisation 9
patients were allocated to TCA and 12 to NaCl (figure 1).
Short-term efficacy
In table 2 and figure 2 the results of outcomes one week
after the last injection are displayed. The TCA-group
showed better outcomes than NaCl-group for the direct
treatment response (p = 0.02), severity of local pain (1.3
{95% CI: 0.3, 2.9} vs 4.3 {95% CI: 2.3, 6.3}; p = 0.03)
and perceived improvement (p = 0.047) but not for total
scores of Dutch AIMS-2 sub items hand- and finger func-
tion (1.9 {95% CI: 0.7, 3.2} vs. 2.7 {95% CI: 1.9, 3.6}; p
= 0.11). Using direct treatment response as the main out-
Table 2: Short term results of 1-2 local injections for de Quervain's tenosynovitis (1 week after last injection)
NaCl (n = 12) TCA (n = 9) p
direct treatment response no response 8 2
partial response, not satisfactory 1 0
partial response, satisfactory 2 1
complete resolution of symptoms 1 6
0.015*
mean severity of pain in the past week (95% CI) 4.3 (2.3-6.3) 1.3 (0.3-2.9)
mean rank 13.1 7.4 0.031§
mean Dutch AIMS-2-HFF (95% CI) 2.7 (1.9-3.6) 1.9 (0.7-3.2)
mean rank 12.4 8.2 0.112§
patient perceived improvement much worse 0 0
worse 2 0
not better not worse 6 2
better 1 1
much better 3 6
0.047*
*Chi-Square test for linear trend
§Mann-Whitney U test
NaCl = NaCl 0.9% (saline)
TCA = triamcinolonacetonide 10 mg/ml
Immediate treatment response one week after one or two  injections Figure 2
Immediate treatment response one week after one 
or two injections.BMC Musculoskeletal Disorders 2009, 10:131 http://www.biomedcentral.com/1471-2474/10/131
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come measure absolute risk reduction was 0.55 (95% CI:
0.34, 0.76) with a number needed to treat of 2 (95% CI:
1, 3).
Long-term efficacy
In table 3 and figures 3 and 4 the results for long-term out-
comes are displayed. Since non-responders to NaCl
required subsequent bail-out injections with TCA and
non-responders to TCA-injections (blinded or bail-out)
were referred to secondary care for operative treatment, we
present the long term results as a cohort study of patients
that had responded to treatment with TCA.
In the NaCl-group three non-responders to NaCl dropped
out because they declined further participation in the
study. They did not receive bailout TCA-injections and
could not be included in the long-term analysis.
The treatment effects of local injections were upheld in
the cohort of participants that responded to TCA injec-
tions (n = 12) during the follow-up period of twelve
Table 3: Long-term results of TCA-responders (n = 12) after 1-2 TCA-injections during follow-up of 12 months
Follow-up period
1 month 3 months 6 months 12 months p-value*
Original study arm TCA
(N = 7)
NaCl
(N = 5)
TCA
(N = 7)
NaCl
(N = 5)
TCA
(N = 7)
NaCl
(N = 5)
TCA
(N = 7)
NaCl
(N = 5)
mean severity of pain (SD) 1.33 (2.05) 1.20 (1.65) 1.25 (1.88) 1.98 (1.82) 2.55 (2.98) 1.32 (1.41) 2.47 (2.93) 1.41 (1.31) 0.67
mean score Dutch AIMS-2-
HFF (SD)
1.20 (0.25) 1.30 (0.45) 1.24 (0.29) 1.47 (0.34) 1.59 (1.16) 1.82 (0.85) 1.50 (0.99) 2.44 (1.27) 0.36
mean perceived improvement 
(SD)
1.44 (0.95) 1.38 (0.90) 1.84 (0.37) 1.25 (0.73) 1.43 (0.73) 1.01 (1.04) 1.60 (0.73) 1.03 (1.01) 0.02
*Friedman test
SD = standard deviation
TCA = triamcinolonacetonide 10 mg/ml
Severity of pain during follow-up of 12 months Figure 3
Severity of pain during follow-up of 12 months. Lines 
connect medians.
Dutch AIMS-2-HFF score during follow-up of 12 months Figure 4
Dutch AIMS-2-HFF score during follow-up of 12 
months. Lines connect medians.BMC Musculoskeletal Disorders 2009, 10:131 http://www.biomedcentral.com/1471-2474/10/131
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months for the outcomes severity of pain (p = 0.67) and
Dutch AIMS-HFF score (p = 0.36), but not for patient per-
ceived improvement (p = 0.02).
Side-effects and serious adverse events
No serious adverse events such as tendon ruptures or deep
skin infections were observed. The most frequent reported
minor side effects were hot flushes (n = 2) and steroid-
flare (n = 6).
Discussion
Our study indicates that one or two local injections with
1 ml of triamcinolonacetonide 10 mg/ml provided by
general practioners leads to improvement of symptoms
one week after injection when compared to placebo injec-
tions. The effect size was considerable with a number to
treat of two.
The effects of steroid injections on functional status of the
hand and wrist were less impressive in this study. Also the
evidence emerging from this study for long term effective-
ness up to one year is less strong than for short term effec-
tiveness, since we were only able to present long term data
for the cohort of steroid responders and short term bene-
ficial effects were only maintained during follow-up for
the severity of pain and the score for the Dutch AIMS-2
sub items hand and finger function and not for patient
perceived improvement. We observed only a few minor
side effects.
Unfortunately we were not able to recruit as many partic-
ipants as we planned. According to the sample-size calcu-
lation, inclusion of 50 participants was required, while we
were only able to include 21 patients. Difficulties with
recruitment of patients for scientific studies in general
practice, especially when incident cases are required, is an
acknowledged problem and this phenomenon is known
as Lasagna's law[15]. Since data on incidence of de Quer-
vain's tenosynovitis in primary care in the Netherlands
were not available, it was difficult for us to predict at the
start of the study whether we would be able to recruit
enough participants.
At baseline assessment the TCA-group and the NaCl-
group were found to be comparable regarding the most
important potentially prognostic indicators and differed
only in male:male ratio, with males overrepresenting the
TCA-group.
If we compare our study to the only other controlled study
(Avci) available so far that assessed effectiveness of corti-
costeroid injections for de Quervain's tenosynovitis the
following strong points can be noted in our study: inclu-
sion was not restricted to pregnant or lactating women, we
used rigorous procedures for allocation concealment and
randomisation, participants and outcome assessors were
blinded, multiple and clearly defined outcome-measures
were used, long term sustainability of effectiveness was
also assessed and our study is the first study using a pri-
mary care study population.
The finding of a success-rate of 78% of steroid injections
is consistent with the success rates found by Jirarattana-
phochai (67-68%) and the systemic review of non-con-
trolled studies by Richie (83%), but lower than in the
controlled trial by Avci (100%), which was the only study
that was included in a Cochrane review [10,12]. A possi-
ble explanation for the difference between the results of
the study by Avci and our study could be that the risk of
bias is probably smaller in our study, since we used more
rigorous procedures for allocation concealment and ran-
domisation and participants and outcome assessors were
blinded. Bias due to inadequate allocation concealment
and randomisation is known to result in overestimation
of treatment effects[16].
We found poorer outcomes for functional status at short-
term assessment using the Dutch AIMS2-HFF measure-
ment tool, which contrasted in relation to the better out-
comes for treatment response, severity of pain and patient
perceived improvement. This could be explained by the
recent finding by Spies-Dorgelo et al that the AIMS-2-HFF
had poor measurement properties regarding reliability
and responsiveness in a cohort of participants with hand
and wrist complaints in general practice[17]. Maybe the
AIMS-2-HFF is not an adequate outcome-tool to assess
functional limitations caused by hand and wrist disorders
in primary care and to evaluate treatment effects.
Our study indicates that local injection therapy with cor-
ticosteroids for de Quervain's tenosynovitis provided by a
primary care provider is an effective alternative to surgical
therapy and we suggest that initial treatment should be
injection therapy with 1-2 local injections with corticos-
teroids and in case of insufficient response or recurrence
the patient should be referred for surgical treatment.
Conclusion
One or two local injections of 1 ml triamcinolonaceto-
nide 10 mg/ml is an effective method of treatment pro-
vided by general practitioners for de Quervain's
tenosynovitis with respect to short term outcomes when
compared to placebo injection. The short-term effects
were maintained for most of the outcome measures dur-
ing the follow-up period of 12 months, but this was based
on outcomes of the cohort of steroid responders and thus
long term effectiveness is less clear.
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